Physician profile
Jonathan Lin
NPI 1821006040
$1,657.47
in general payments reported to CMS, 2019-2025
23 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $188 · 2021: $156 · 2022: $156 · 2023: $248 · 2024: $173 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Education: $48.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.89 |
| Education | $48.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $261.99 | 2019-2021 | |
| Abbvie INC. | $195.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $173.78 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $163.94 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $113.69 | 2021-2025 | Freestyle Libre 3, Eterna |
| Otsuka America Pharmaceutical, INC. | $89.54 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $68.80 | 2023-2025 | |
| Lilly USA, LLC | $58.07 | 2023-2025 | Emgality, Jardiance, Zepbound |
| Lundbeck LLC | $54.52 | 2025 | Rexulti |
| Genentech USA, INC. | $51.54 | 2019-2022 | |
| Janssen Biotech, INC. | $48.95 | 2023 | Stelara, Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.86 | 2020-2025 | Ofev |
| Sanofi Pasteur INC. | $47.00 | 2023 | |
| Sanofi-Aventis U.S. LLC | $46.03 | 2024-2025 | |
| Dexcom, INC. | $40.46 | 2025 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.30 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $35.40 | 2019 | |
| Medtronic, INC. | $27.74 | 2022 | |
| Pfizer INC. | $21.57 | 2025 | |
| Amarin Pharma, INC. | $21.41 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.13 | 2020 | |
| Acerus Pharmaceuticals Corporation | $17.86 | 2022 | |
| Merck Sharp & Dohme LLC | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.